Fermenta Biotech

Thane, India Founded: 1986 • Age: 40 yrs Listed
Manufacturer of Vitamin D3, enzymes, and environmental solutions
Request Access
Report Incorrect Data
Page last updated

About Fermenta Biotech

Fermenta Biotech is a publicly listed company based in Thane (India) founded in 1986. Manufacturer of Vitamin D3, enzymes, and environmental solutions. The company has 855 employees. Fermenta Biotech has completed 1 acquisition, including AGD Nutrition. Its chief executive, as recorded, is Prashant Nagre. Its Indian entity Fermenta Biotech Limited reported revenue of ₹555 Cr. Fermenta Biotech offers products and services including Vitamin D3 and Enzymes. Its focus areas include Traditional Nutraceuticals, Dietary Supplements and Vitamins & Minerals.

Company details

Fermenta Biotech was founded in 1986 in Thane, India, and operates in the biotechnology sector. Various forms of Vitamin D3 are produced for pharmaceutical, dietary supplement, and food applications. Enzymes are offered for antibiotic synthesis and biopharmaceutical processes. Solutions for wastewater management and treatment are also provided. A real estate development arm supports the core operations.

  • Headquarters Thane, India
  • Employees 855
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Phone
    •••• ••••
  • Website fermentabiotech.com
  • Social LinkedIn X Facebook YouTube
  • Legal Name Fermenta Biotech Ltd
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹1,303 Cr

    FERMENTA · NSE

  • Share Price
    ₹439.10

    -0.82% today

  • Revenue
    ₹525 Cr

    FY 2025-26 · +11.9% YoY

  • EBITDA
    ₹101 Cr

    Margin 19.2%

  • Net Profit
    ₹62.91 Cr

    FY 2025-26 · -22.4% YoY

  • P/E (TTM)
    24.1x

    P/B 3.2x

  • ROE
    18.3%

    ROCE 20.7%

  • Debt / Equity
    0.30

    Interest cover 16.0x

  • Latest Funding Round
    $8.71M (USD), Post-IPO

    Dec 2010

  • Investors
    Evolvence India

    & 1 more

  • Employee Count
    855
  • Investments & Acquisitions
    AGD Nutrition

Products & Services of Fermenta Biotech

Fermenta Biotech offers a comprehensive portfolio of products and services, including Vitamin D3 and Enzymes.

Vitamin D3
Nutritional Ingredients

Vitamin D3 is manufactured for applications in pharmaceuticals, supplements, and food fortification

Enzymes
Biotechnology Products

Enzymes are provided for antibiotic synthesis and eco-friendly manufacturing practices in various sectors

Apps and channels of Fermenta Biotech

its YouTube channel Fermenta Biotech Limited has 438 subscribers and 15 videos.

Fermenta Biotech Limited
YouTube 438 subscribers 15 videos Science & Technology
Open channel

Videos from Fermenta Biotech

The most watched videos on Fermenta Biotech's YouTube channel, Fermenta Biotech Limited (438 subscribers). Click a video to play it here.

Fermenta Biotech Limited: Corporate Video
3.3K views
Employee Safety Video: Dahej Manufacturing Facility
1.7K views
Employee Safety Video: Kullu Manufacturing Facility
1.4K views
Employee Safety Video: R&D Centre, Thane
563 views

More on Fermenta Biotech Limited.

Funding Insights of Fermenta Biotech

  • Total Rounds 2
  • Last Round Post-IPO — $8.71M
  • First Round $1.51M

    (Jun 2010)

  • Investors Count 2

All 2 funding rounds of Fermenta Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2010$8.71MPost-IPO––
Evolvence India
Jun 2010$1.51MPost-IPO––
Allegro Advisors
Valuation history

2 investors in total: 2 institutional.

Investors in Fermenta Biotech

Fermenta Biotech has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Evolvence India and Allegro Advisors.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Evolvence India
Investment platform for private markets in India focusing on venture capital and private equity.
2006evolvenceindia.comMumbai, India
Allegro Advisors
Financial advisory and investment banking services in the finance sector.
2002allegroadvisors.comBengaluru, India
Premium access

Investor details for Fermenta Biotech

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Fermenta Biotech Limited (Fermenta Biotech)

Fermenta Biotech Limited is the primary company behind Fermenta Biotech. The board of Fermenta Biotech Limited currently have 9 directors; the longest-serving is Satish Varma Azad Nadimpally, appointed in 2003. 13 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Satish Varma Azad Nadimpally
DIN 00003255
Whole-time director01 Jul 200323 yrs 3 moFermenta Biotech Limited
Rajeshwari Datla
DIN 00046864
Director21 Jul 200521 yrs 3 moFermenta Biotech Limited
Krishna Vasantkumar Datla
DIN 00003247
Whole-time director09 May 201016 yrs 5 moFermenta Biotech Limited
Anupama Datla Desai
DIN 00217027
Whole-time director27 Sep 20197 yrs 1 moFermenta Biotech Limited
Rajashri Santosh Kumar Ojha
DIN 07058128
Director01 Apr 20206 yrs 6 moFermenta Biotech Limited
Prashant Prabhakar Nagre
DIN 09165447
Managing Director06 May 20215 yrs 5 moFermenta Biotech Limited
Pramod Kasat
DIN 00819790
Director30 May 20224 yrs 5 moFermenta Biotech Limited
Pradeep Manjunath Chandan
DIN 00200067
Director12 Feb 20242 yrs 8 moFermenta Biotech Limited
Ramanand Mundkur
DIN 03498212
Director14 Nov 20241 yr 11 moFermenta Biotech Limited

People of Fermenta Biotech

28 people are tracked at Fermenta Biotech (9 in leadership, 19 in team); the tracked headcount is 855.

NameRoleGroup
Prashant Nagre
CEOLeadership
Suresh Uniyal
Vice President-manufacturingLeadership
Prashant Gudhate
President Corporate Quality, Regulatory & FormulationsLeadership
Harold Mascarenhas
Head-security OperationsLeadership
V.k. Raveendranath
Vice President- Human Resources & AdministrationLeadership
Dhanya Ajit
Assistant General Manager - HRLeadership
Uddhav Deshmukh
Vice President Of ManufacturingLeadership
Sumesh Gandhi
Group Chief Financial OfficerLeadership
Sahil Desai
Vice President - Business Development & MarketingLeadership
Govind Thakur
Dy.manager ProductionTeam
Madhuri D.
Human Resources ExecutiveTeam
Navdeep Jethi
Asst. Manager (project & Maintenance)Team
Pradip Devare
Executive WarehouseTeam
Abhijeeet Bhosale
Maintenance EngineerTeam
Swapnil Waje
Manager-engineering And MaintenanceTeam
Nikhil Sharma
Executive EngineerTeam
Sanjeev Thakur
Deputy Manager ITTeam
Rajesh Churi
Sr.manager Technical Operation And QATeam
Rakesh Mayatra
Deputy Manager Of Information TechnologyTeam
Omkar Patil
Maintenance And Utility EngineerTeam

8 more people are available in the full profile.

Premium access

Complete people profiles for Fermenta Biotech

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Fermenta Biotech

Fermenta Biotech is a publicly listed company on the BSE with ticker symbol FERMENTA in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date05 Feb 2000
  • Listed onBOM: 506414
  • Listed entityFermenta Biotech Ltd
  • Exchange sectorHealth technology
  • ISININE225B01021
  • Share price₹280.55 (-2.82% on the day) · 2026-05-11
  • Market capitalisation₹850 Cr
  • Price to earnings9.3
  • EPS (diluted, trailing year)₹30.03
  • Dividend yield0.87%
  • Volume (last session)6,600
  • Analyst consensusNo rating

Financials of Fermenta Biotech

Exchange-reported figures of Fermenta Biotech Limited, the listed company behind Fermenta Biotech (NSE: FERMENTA).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹525 Cr
+11.9% YoY
EBITDA
₹101 Cr
-8.6% YoY
Profit After Tax
₹62.91 Cr
-22.4% YoY
Net Worth
₹406 Cr
+12.0% YoY
Total Assets
₹541 Cr
+8.7% YoY
Total Debt
₹113 Cr
-1.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue525469336350399377292
Revenue growth+11.9%+39.9%-4.1%-12.2%+5.6%+29.3%-
EBITDA10111120.47(10.28)62.3682.6966.19
EBITDA margin+19.2%+23.5%+6.1%-2.9%+15.7%+21.9%+22.7%
Profit before tax95.8683.22(9.87)(51.30)26.9651.6343.42
Net profit62.9181.06(16.63)(23.95)15.4745.6457.78
Net profit margin+12.0%+17.3%-5.0%-6.8%+3.9%+12.1%+19.8%
EPS (₹)25.0326.35(7.99)(17.70)5.3515.7720.63
Balance sheet
Total assets541498465562622598539
Net worth406363289315372361309
Total debt113115139220239232224
Cash & bank41.3471.7059.8358.3333.6144.5333.11
Net working capital282219159175229220209
Cash flow
Cash from operations92.8340.9010511643.4462.6034.46
Cash from investing(43.00)(0.16)(15.50)(55.36)(26.04)(40.94)(43.66)
Cash from financing(42.29)(50.87)(90.85)(41.38)(21.58)(1.14)(47.45)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue12212213713013614015695.03
Revenue growth (YoY)-10.6%-13.1%-12.2%+37.0%+74.4%---
Other income4.3714.143.125.438.773.892.232.88
EBITDA18.0520.0022.7726.6328.2336.9553.2718.78
EBITDA margin+14.8%+16.5%+16.6%+20.5%+20.7%+26.4%+34.0%+19.8%
Depreciation5.205.115.375.415.815.866.086.15
Interest2.542.823.032.583.112.994.083.69
Profit before tax14.6826.2117.4924.0728.0831.9945.3411.82
Tax5.167.615.466.066.48(1.34)7.450.70
Net profit9.5218.6012.0318.0121.6033.3337.8911.12
EPS (₹)3.346.614.346.157.4711.7912.713.94
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue450431307329388373299
Revenue growth+4.6%+40.2%-6.6%-15.2%+4.1%+24.6%-
EBITDA91.6710128.33(20.61)76.8294.7370.45
EBITDA margin+20.4%+23.4%+9.2%-6.3%+19.8%+25.4%+23.5%
Profit before tax89.2274.42(4.62)(57.99)42.5763.2247.55
Net profit55.2171.71(7.75)3.0730.2652.0961.77
Net profit margin+12.3%+16.7%-2.5%+0.9%+7.8%+14.0%+20.6%
EPS (₹)22.4223.18(6.49)(19.75)10.4818.0122.07
Balance sheet
Total assets563519494585649610544
Net worth423380314336396370313
Total debt113115139219241234226
Cash & bank18.0261.9556.6455.1130.7541.3032.37
Net working capital270218168172251235216
Cash flow
Cash from operations82.6333.8310512450.4162.9629.83
Cash from investing(46.00)0.41(15.15)(63.47)(32.46)(43.61)(39.19)
Cash from financing(42.15)(50.91)(90.86)(41.25)(21.76)(1.32)(47.63)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue11211011410711912214689.54
Revenue growth (YoY)-6.0%-10.0%-21.9%+19.6%+63.7%---
Other income4.9015.173.435.538.843.882.222.95
Total expenses88.8688.0492.8884.1596.4989.3696.1274.05
EBITDA22.9821.8421.3622.9722.5332.6850.1315.49
EBITDA margin+20.5%+19.9%+18.7%+21.4%+18.9%+26.8%+34.3%+17.3%
Depreciation5.195.085.175.135.555.605.825.89
Interest2.542.773.032.593.112.994.093.69
Profit before tax20.1529.1616.5920.7822.7127.9742.448.86
Tax5.167.584.836.066.48(1.34)7.450.70

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue12212213713013614015695.03
Revenue growth (YoY)-10.6%-13.1%-12.2%+37.0%+74.4%---
Other income4.3714.143.125.438.773.892.232.88
EBITDA18.0520.0022.7726.6328.2336.9553.2718.78
EBITDA margin+14.8%+16.5%+16.6%+20.5%+20.7%+26.4%+34.0%+19.8%
Depreciation5.205.115.375.415.815.866.086.15
Interest2.542.823.032.583.112.994.083.69
Profit before tax14.6826.2117.4924.0728.0831.9945.3411.82
Tax5.167.615.466.066.48(1.34)7.450.70
Net profit9.5218.6012.0318.0121.6033.3337.8911.12
EPS (₹)3.346.614.346.157.4711.7912.713.94
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue525469336350399377292
Revenue growth+11.9%+39.9%-4.1%-12.2%+5.6%+29.3%-
Other income29.2611.8211.818.608.148.2512.32
Total expenses424359315360336295226
Employee cost82.5965.1058.5558.0062.9758.2250.03
EBITDA10111120.47(10.28)62.3682.6966.19
EBITDA margin+19.2%+23.5%+6.1%-2.9%+15.7%+21.9%+22.7%
Depreciation21.7024.2224.7228.2525.5620.3115.00
Interest12.6614.8917.4321.3717.9819.0020.09
Profit before tax95.8683.22(9.87)(51.30)26.9651.6343.42
Tax25.616.8014.141.8311.899.10(16.10)
Net profit62.9181.06(16.63)(23.95)15.4745.6457.78
Net profit margin+12.0%+17.3%-5.0%-6.8%+3.9%+12.1%+19.8%
EPS (₹)25.0326.35(7.99)(17.70)5.3515.7720.63
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.3414.5814.4414.4314.4214.4214.42
Reserves & surplus392348274301358346295
Shareholders' funds (net worth)406363289315372361309
Minority interest(5.67)(4.16)(3.70)(2.75)(0.68)(0.30)0.01
Secured loans109109132217236229220
Unsecured loans4.445.546.502.683.042.863.69
Total debt113115139220239232224
Total liabilities541498465562622598539
Assets
Gross block386372402377393331248
Net block220227269267299263200
Capital work in progress13.1115.911.6245.0234.5756.9170.77
Investments0.420.490.433.150.290.250.26
Inventories15312487.38130159162129
Sundry debtors11295.2369.8341.6587.0968.0169.77
Cash & bank balances41.3471.7059.8358.3333.6144.5333.11
Loans & advances82.5544.6624.7120.1333.8534.8052.54
Total current assets388335242250314310284
Total current liabilities10711682.5774.7784.5989.2975.05
Net working capital282219159175229220209
Total assets541498465562622598539
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash6.6316.7517.75(1.61)2.29(18.22)38.42
Net cash from operating activities92.8340.9010511643.4462.6034.46
Net cash from investing activities(43.00)(0.16)(15.50)(55.36)(26.04)(40.94)(43.66)
Net cash from financing activities(42.29)(50.87)(90.85)(41.38)(21.58)(1.14)(47.45)
Net change in cash7.55(10.12)(1.00)19.37(4.17)20.52(56.65)
Closing cash41.3471.7059.8358.3333.6144.5333.11
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+11.9%+39.9%-4.1%-12.2%+5.6%+29.3%-
EBITDA growth-8.6%+439.9%+299.1%-116.5%-24.6%+24.9%-
PBT growth+15.2%+9998.0%+80.8%--47.8%+18.9%-66.3%
Net income growth-22.4%+587.4%+30.6%-254.8%-66.1%-21.0%-
Revenue CAGR (3Y)+14.5%+5.6%-3.8%+6.3%-0.4%+7.7%+21.2%
EBITDA CAGR (3Y)-+21.0%-37.2%--25.3%-3.9%+76.9%
Profitability & leverage
Net income margin+13.4%+16.3%-7.2%-15.2%+3.8%+11.3%+20.4%
Return on capital employed+20.7%+20.2%+3.0%-0.2%+7.4%+12.4%+12.6%
Return on net worth+18.3%+23.5%-5.8%-7.6%+4.1%+12.7%+21.3%
Debt / equity0.300.390.590.670.640.680.77
Long-term debt / equity0.040.090.180.270.310.320.43
Interest cover15.9717.26-410.12-55.4648.8630.4639.25
Efficiency & per share
Fixed asset turnover1.391.210.860.911.101.301.27
Inventory turnover3.804.453.092.422.482.592.71
Debtors turnover5.085.696.025.445.145.484.33
EPS (₹)25.0326.35(7.99)(17.70)5.3515.7720.63
Dividend per share (₹)3.752.501.251.251.252.505.00
Book value per share (₹)141.68124.33100.04109.27129.00125.00107.27
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue11211011410711912214689.54
Revenue growth (YoY)-6.0%-10.0%-21.9%+19.6%+63.7%---
Other income4.9015.173.435.538.843.882.222.95
Total expenses88.8688.0492.8884.1596.4989.3696.1274.05
EBITDA22.9821.8421.3622.9722.5332.6850.1315.49
EBITDA margin+20.5%+19.9%+18.7%+21.4%+18.9%+26.8%+34.3%+17.3%
Depreciation5.195.085.175.135.555.605.825.89
Interest2.542.773.032.593.112.994.093.69
Profit before tax20.1529.1616.5920.7822.7127.9742.448.86
Tax5.167.584.836.066.48(1.34)7.450.70
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue450431307329388373299
Revenue growth+4.6%+40.2%-6.6%-15.2%+4.1%+24.6%-
Other income30.8711.688.158.467.536.6212.31
Total expenses359330279350311278229
Employee cost74.1460.1053.9353.8159.3657.5050.03
EBITDA91.6710128.33(20.61)76.8294.7370.45
EBITDA margin+20.4%+23.4%+9.2%-6.3%+19.8%+25.4%+23.5%
Depreciation20.9423.1723.7024.4923.6719.0314.94
Interest12.3814.8417.4021.3518.1119.1020.27
Profit before tax89.2274.42(4.62)(57.99)42.5763.2247.55
Tax24.966.8014.14(0.97)12.3311.26(16.12)
Net profit55.2171.71(7.75)3.0730.2652.0961.77
Net profit margin+12.3%+16.7%-2.5%+0.9%+7.8%+14.0%+20.6%
EPS (₹)22.4223.18(6.49)(19.75)10.4818.0122.07
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.3414.5814.4414.4314.4214.4214.42
Reserves & surplus408365300322382356298
Shareholders' funds (net worth)423380314336396370313
Secured loans109109132217236229220
Unsecured loans4.445.546.502.684.794.655.56
Total debt113115139219241234226
Total liabilities563519494585649610544
Assets
Gross block376362384358377315244
Net block220226267257287250197
Capital work in progress13.1115.911.6245.0234.5756.9170.77
Investments11.623.693.6315.3512.9912.951.11
Inventories13194.4878.61110130133114
Sundry debtors13712077.1367.4111896.1277.44
Cash & bank balances18.0261.9556.6455.1130.7541.3032.37
Loans & advances73.6243.8725.8518.2737.1037.7559.10
Total current assets360321238251315308282
Total current liabilities89.2210370.2078.6764.1272.8065.96
Net working capital270218168172251235216
Total assets563519494585649610544
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash(3.12)13.5614.54(4.49)(0.94)(18.96)38.02
Net cash from operating activities82.6333.8310512450.4162.9629.83
Net cash from investing activities(46.00)0.41(15.15)(63.47)(32.46)(43.61)(39.19)
Net cash from financing activities(42.15)(50.91)(90.86)(41.25)(21.76)(1.32)(47.63)
Net change in cash(5.52)(16.67)(0.98)19.03(3.81)18.03(56.99)
Closing cash18.0261.9556.6455.1130.7541.3032.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+4.6%+40.2%-6.6%-15.2%+4.1%+24.6%-
EBITDA growth-9.0%+255.6%+237.5%-126.8%-18.9%+34.5%-
PBT growth+19.9%+9998.0%+92.0%--32.7%+33.0%-60.7%
Net income growth-23.0%+1025.3%-352.4%-89.9%-41.9%-15.7%-
Revenue CAGR (3Y)+11.0%+3.5%-6.3%+3.2%-1.3%+210.0%+278.5%
EBITDA CAGR (3Y)-+9.5%-33.1%--18.5%--
Profitability & leverage
Net income margin+14.3%+15.7%-6.1%-17.3%+7.8%+13.9%+21.3%
Return on capital employed+18.8%+17.6%+4.1%+3.8%+9.7%+14.3%+13.4%
Return on net worth+16.0%+19.5%-2.4%+0.8%+7.9%+15.2%+22.7%
Debt / equity0.280.370.550.630.620.670.77
Long-term debt / equity0.040.080.160.260.300.320.43
Interest cover17.5019.13375.81-47.3434.0725.2336.52
Efficiency & per share
Fixed asset turnover1.221.160.830.891.121.331.33
Inventory turnover4.004.973.262.752.963.032.99
Debtors turnover3.504.364.253.553.634.304.20
EPS (₹)22.4223.18(6.49)(19.75)10.4818.0122.07
Dividend per share (₹)3.752.501.251.251.252.505.00
Book value per share (₹)147.47130.26108.83116.45137.26128.42108.36

Investments & Acquisitions by Fermenta Biotech

Fermenta Biotech has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AGD Nutrition.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
AGD Nutrition
Nutrition products are manufactured and marketed by AGD Nutrition.
agdnutrition.comLake Dallas, United States2002Dec 2020$1.26M
Premium access

Complete acquisition details for Fermenta Biotech

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Fermenta Biotech

5 dated milestones of Fermenta Biotech across 34 years, from founding to its latest funding, stage changes and deals.

  1. Founded Fermenta Biotech is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $1.5M.
  4. Funding Latest funding round, Post-IPO, of $8.7M.
  5. Acquisition Acquires AGD Nutrition.

Web traffic of Fermenta Biotech

The website of Fermenta Biotech (fermentabiotech.com) receives about 8.3K visits a month and ranks #2,177,831 among all websites worldwide, #2,957 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    8.3K

    ▼ 14.8% vs previous month

  • Unique visitors
    4.9K

    per month

  • Global rank
    #2,177,831

    among all websites

  • Category rank
    #2,957

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Fermenta Biotech. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Rubicon Research
rubicon.co.in
100%
7.6K#2,066,760View details
Akums
akums.in
87%
25.5K#1,037,095View details
Meyer Organics
meyer.co.in
58%
19.3K#1,447,065View details
AdvaCare Pharma
advacarepharma.com
53%
680.7K#373,777View details
Podo Medi
podomedi.com
40%
#9,010,659View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 9 similar websites and full traffic analytics for Fermenta Biotech

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 9 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Fermenta Biotech (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M5,180
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.21 B25,870
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Fermenta Biotech

Fermenta Biotech Board Approves Proposal For Raising Funds
Reuters • 10 months ago
Fermenta Biotech Board Approves 1.10 Billion Rupees Capacity Addition
Reuters • 10 months ago
Fermenta Biotech Makes Further Investment In Wholly-Owned Subsidiary
Reuters • 1 year ago
Manali Petrochemicals Signs Pact With Fermenta Biotech
Reuters • 1 year ago
Fermenta Biotech To Sell Its Commercial Office Premises At Worli, Mumbai
Reuters • 1 year ago
Fermenta Biotech Executes MoU To Sell Commercial Office Premises At Mumbai
Reuters • 2 years ago
Fermenta Biotech Receives EU GMP Certification For Its Dahej Manufacturing Facility
Reuters • 2 years ago
Fermenta Biotech Receives EU GMP Compliance Certificate For Manufacturing Facility In Gujarat
Reuters • 2 years ago
Fermenta Biotech Executes Sale Deed To Sell Substantial Portion Of Land Situated At Village Takve Budruk
Reuters • 2 years ago
Fermenta Biotech Says Co's Factory At Kullu, Himachal Pradesh Restored To Normalcy Since August 11, 2023
Reuters • 3 years ago
Premium access

Complete news archive for Fermenta Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Fermenta Biotech

Fermenta Biotech was founded in 1986 and raised its 1st funding round 24 years after it was founded.

Fermenta Biotech is headquartered in Thane, India. It is registered at Thane, Maharashtra, India.

Prashant Nagre is the CEO of Fermenta Biotech, as recorded in our data.

Fermenta Biotech has 855 employees.

The primary company behind Fermenta Biotech, Fermenta Biotech Limited, reported revenue of ₹555 Cr for FY 2026, up 12% year on year.

Fermenta Biotech was founded in 1986 in Thane, India, and operates in the biotechnology sector. Various forms of Vitamin D3 are produced for pharmaceutical, dietary supplement, and food applications. Enzymes are offered for antibiotic synthesis and biopharmaceutical processes. Solutions for wastewater management and treatment are also provided. A real estate development arm supports the core operations.

Fermenta Biotech offers Vitamin D3 and Enzymes.

Yes, Fermenta Biotech is publicly traded on BSE under the ticker symbol FERMENTA.

Fermenta Biotech has made 1 acquisition, including AGD Nutrition.

Fermenta Biotech has 2 investors. Key investors include Evolvence India, and Allegro Advisors.

Fermenta Biotech operates through Fermenta Biotech Limited.

The legal entities of Fermenta Biotech currently have 11 directors, including Rajashri Santosh Kumar Ojha, Anupama Datla Desai, Satish Varma Azad Nadimpally and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available